MAPK7 and cholangiocarcinoma: Gentilini et al. demonstrated that ERK5 promotes proliferation, migration, and invasion in cholangiocarcinoma; silencing ERK5 reduces the expression of angiogenic factors VEGF and angiopoietin 1, subsequently inhibiting these phenotypes [106].